FAQs

Overview of key ADC drug targets with research reagents. Covers HER2, TROP2, Claudin 18.2, Nectin-4, CD33, BCMA, Mesothelin, and Tissue Factor — with target biology, approved ADCs, and available antibodies, proteins, and biosimilars.

Overview of the tumor microenvironment for researchers. Covers immune cell populations (TILs, TAMs, MDSCs, Tregs, DCs), stromal components (CAFs, endothelial cells), key signaling pathways (TGF-beta, CXCR4, CSF1R), and reagents for TME profiling by flow cytometry, IHC, and multiplex IF.

Research reagents for PD-1 and PD-L1 studies. Covers target biology, checkpoint blockade mechanism, available antibody clones (detection and neutralizing), recombinant proteins, and biosimilar reference antibodies for PK/ADA assays.

Research reagents for CTLA-4 (CD152) studies. Covers target biology, role in T cell priming, approved drugs, and available antibodies, proteins, and biosimilars.

Research reagents for HER2/ERBB2 studies in breast cancer, gastric cancer, and beyond. Covers target biology, HER2 signaling, IHC scoring, and available antibodies, proteins, and biosimilar reference antibodies.

Research reagents for EGFR/ERBB1 studies in lung cancer, CRC, and HNSCC. Covers EGFR signaling, mutation landscape, targeted therapies, and available antibodies, proteins, and biosimilars.

Research reagents for CD20 studies in lymphoma, leukemia, and autoimmune disease. Covers B cell biology, CD20-targeted therapies, and available antibodies, proteins, and biosimilars.

Research reagents for next-generation checkpoint targets LAG-3, TIGIT, and TIM-3. Covers biology, clinical development status, exhaustion phenotyping, and available antibodies, proteins, and biosimilars.

Research reagents for VEGF/VEGFR and angiogenesis studies. Covers the VEGF signaling axis, anti-angiogenic therapies, and available antibodies, proteins, and biosimilars.

Research reagents for costimulatory checkpoint agonists OX40 and 4-1BB. Covers target biology, agonist vs antagonist mechanisms, and available antibodies, proteins, and biosimilars.